Drug intelligence / Profile preview

pitavastatin + ceftobiprole

Development stage
Unknown
Lead developer
Basilea Pharmaceutica
Modality
Small Molecules
Administration
Oral, Intravenous
01

Overview

Pitavastatin + ceftobiprole is a combination of two pharmaceutical agents with distinct mechanisms and indications. Pitavastatin is an oral small molecule statin used to lower high cholesterol and triglyceride levels in the blood while increasing HDL cholesterol. It works by inhibiting HMG-CoA reductase, the rate-limiting enzyme in cholesterol biosynthesis[1]. Ceftobiprole is a fifth-generation injectable cephalosporin antibiotic (marketed as Zevtera) indicated for the treatment of Staphylococcus aureus bloodstream infections (bacteremia), acute bacterial skin and skin structure infections (ABSSSI), and community-acquired bacterial pneumonia (CABP). Ceftobiprole acts by binding to penicillin-binding proteins (PBPs), including PBP2a in MRSA strains, thereby inhibiting cell wall synthesis and causing bacterial cell death[2][3][4][5][6].

Brand names
LivaloZypitamagZevtera
Other names
pitavastatin calciumceftobiprole medocaril
02

Targets

RXRA (Retinoid X receptor alpha)PBP2x (Penicillin-binding protein 2x)PBP5 (D-alanyl-D-alanine carboxypeptidase DacA)HMGCR (3-hydroxy-3-methylglutaryl-coenzyme A reductase)PBP2B (Penicillin-binding protein 2B)NR4A2 (Nuclear receptor subfamily 4 group A member 2)

Beyond the preview

Go deeper on pitavastatin + ceftobiprole.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on pitavastatin + ceftobiprole.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call